The U.S. has approved BioLineRx’s Aphexda (motixafortide) in combination with filgrastim (G-CSF) to improve the process of autologous hematopoietic stem cell transplant (AHSCT) for people with multiple myeloma. AHSCT’s success depends on efficacious mobilization of healthy blood stem cells into the bloodstream for collection and subsequent transplant.
Some multiple myeloma cells acquire mutations that allow them to act in disguise and to escape the effects of T-cell therapies, according to a study that calls for the screening of patients for these mutations for better disease management. “Recognizing these mutations and gaining a clearer understanding of the…
Most patients with hard-to-treat multiple myeloma given NXC-201 — Nexcella’s experimental point-of-care CAR T-cell therapy — as part of a clinical trial in Israel have responded to treatment, with the response appearing to be long-lasting and the side effects manageable. That’s according to up to nearly 1.5 years…
SP-3164, an investigational small molecule protein degrader, showed potential for improved anti-multiple myeloma activity over similar approved compounds. That’s according to preclinical data from its developer Salarius Pharmaceuticals that showed SP-3164 triggered the death of lab-grown cancer cells and held back cancer growth in a mouse model of…
The European Commission has approved Pepaxti (melphalan flufenamide, also called melflufen), a medicine by Oncopeptides to be used in combination with dexamethasone, making it available to adults with hard-to-treat multiple myeloma in Europe. The approval came after the Committee for Medicinal Products for Human Use, an arm of…
Oncopeptides received a positive opinion from an arm of the European Medicines Agency (EMA) that is expected to take the company one step closer toward European Union approval to market Pepaxti (melphalan flufenamide, also called melflufen) in combination with dexamethasone for hard-to-treat multiple myeloma. With the Committee for Medicinal…
Get regular updates to your inbox.